TEL AVIV, Israel, Oct. 7, 2024 /PRNewswire/ — Medinol Ltd. is pleased to announce the successful first-in-human (FIH) implantation of the ChampioNIR Drug-Eluting Peripheral Stent by Dr. Gerard S. Goh and Thodur Vasudevan from the Alfred Hospital in Melbourne, Australia, represent a revolutionary advance in the mechanics, durability and drug delivery of peripheral drug-eluting stents.
The ChampioNIR Drug-Eluting Peripheral Stent System represents a breakthrough technology designed to improve patient outcomes and procedural success. In a novel hybrid mechanical design, radial support is provided by the metallic component of the stent, while longitudinal structure is provided by a bioabsorbable polymeric mesh that provides unmatched flexibility and long-term durability even in the most difficult anatomical conditions. In addition, a unique drug elution paradigm releases the drug from the entire cylindrical region of the stent, dramatically reducing diffusion distances and allowing, for the first time, therapeutic dosing of a large peripheral vessel with a “limus” drug over an extended period of time is.
“We were impressed by the performance of ChampioNIR and its ease of use,” said Prof. Gerard S. Goh, Head of Interventional Radiology at Alfred Hospital. “The smooth deployment mechanism made precise positioning of the stent very easy.”
Dr. Yoram Richter, CEO of Medinol, added: “Medinol is pleased to bring into clinical practice the culmination of years of research and development of novel stent designs tailored to address previously unsolved clinical challenges in vascular interventions.”
The CHAMPIONSHIP First-In-Human study will enroll a total of 30 patients across 7 sites in Australia and the United States. Prof. Sahil Parikh, leader of the CHAMPIONSHIP trial, commented: “The ChampioNIR stent represents a breakthrough in the treatment of SFA lesions. I look forward to seeing this device come to life after years of development.”
About Medinol
Founded in 1992, Medinol is a private company with offices in the United States and Israel and employs over 300 people.
Medinol has more than 30 years of experience in the stent market and is committed to changing the paradigms in disease diagnosis and treatment. By developing cutting-edge scaffolds for stent implantation in various areas of the human body, dramatically reducing complications in structural heart surgery, and providing real-time insights into physiological metrics through implantable microsensors, Medinol is looking years into the future to pioneer medical devices develop. For more information, see www.medinol.com.
Contact: Jeff Roach [email protected]
WANT YOUR COMPANY’S NEWS FEATURED ON PRNEWSWIRE.COM?
440k+
Newsrooms &
Influencers
9k+
Digital Media
Outlets
270k+
Journalists
Opted In
